Curtis Ruegg will join Amphivena Therapeutics as president and CEO as the company’s founder Jeanmarie Guenot transitions to an advisory role. The San Francisco company, which has raised $88.5 million from outside investors, is is developing a type of immunotherapy called T cell engagers.
Ruegg joins Amphivena from Parvus Therapeutics, where he held the same roles. He previously held leadership positions at Revance (NASDAQ: [[ticker:RVNC]]), CoTherix, Intermune (now owned by Roche), AP Cells, and Dendreon.